Researchers from the Chinese Academy of Sciences and collaborators reported on the discovery and preclinical characterization of JN-122, a potent spiroindoline derivative that showed a Ki value of 0.7 nM against MDM2.
Researchers from Sirnaomics Inc. presented preclinical evaluation of novel intravenous polypeptide nanoparticle designed to simultaneously deliver two siRNAs, silencing TGF-β and COX-2.
IMU Biosciences Ltd. has raised £11.5 million (US$14.7 million) in a series A round to further develop and commercialize profiling technology that can identify from a blood sample which of more than 2,000 cell types are present in an individual’s immune system.
Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have synthesized fibroblast growth factor receptor (FGFR) inhibitors reported to be useful for the treatment of cancer and achondroplasia.
RSS
